Objective: To evaluate the effect of CapeOX (capecitabine-oxaliplatin) new adjacent chemotherapy and hepatectomy on the patients with colorectal cancer and unresectable liver metastases. Methods:Fifty-one patients with liver metastases from colorectal cancer, which meeting defined criteria of unresectability. Frist, the patients received CapeOX new adjacent chemotherapy，and assessed every 2 weeks. Patients whose liver metastases became resectable after treatment with CapeOX were considered to undergo liver metastasectomy， and then continued on further treatment with CapeOX after surgery. The therapeutic effects, including surgical response，rate of hepatectomy，postoperative complications and recurrence， and survival state, were evaluated. The expression of epidermal growth factor receptor (EGFR) in the primary lesions of the patients was also analyzed. Results:These 51 patients received CapeOX new adjacent chemotherapy for 1-8 weeks (median therapeutic time was 4 weeks). In 22 patients (43.1%) the liver metastases responded to CapeOX treatment， and 15 of them (29.4%) underwent curative hepatectomy; 19 patients (37.2%) had no response to CapeOX treatment，and their median survival time was 12 months; the remaining 17 patients with stable disease or partial responses did not undergo curative surgery， and their median survival time was 19 months. Five of 15 patients who underwent curative hepatectomy had various complications， but no postoperative mortality. At median follow-up of 21 months in the hepatectomy group，relapse and death occurred in 6 and 4 cases respectively. The expression of EGFR was associated with the progression of the metastatic colorectal cancer. Conclusions:CapeOX new adjacent chemotherapy can convert the unresectable liver metastases to be resectable in some patients. The combination of CapeOX with radical excision may can improve the outcome in selected patients with metastatic colorectal cancer.